Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12

Although Trastuzumab, an anti-HER2 antibody, benefits certain patients with HER2-overexpressing breast cancer, de novo or acquired trastuzumab resistance remains a haunting issue. EGFRvIII, co-expressing with HER2 in some breast tumors, indicates a poor clinical prognosis. However, the role of EGFRv...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wen, Bi, Yanyu, Zhang, Jiqin, Kong, Juan, Jiang, Hua, Tian, Mi, Li, Kesang, Wang, Biao, Chen, Cheng, Song, Fei, Pan, Xiaorong, Shi, Bizhi, Kong, Xianming, Gu, Jianren, Cai, Xiumei, Li, Zonghai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770741/
https://www.ncbi.nlm.nih.gov/pubmed/26474285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4770741/
https://www.ncbi.nlm.nih.gov/pubmed/26474285

Ejemplares similares